April 08, 2008
The FDA has approved GlaxoSmithKline's Rotarix (rotavirus vaccine, live, oral) for the prevention of rotavirus gastroenteritis in infants. Rotarix is indicated to offer protection against the most commonly circulating rotavirus types in the US and allow infants to complete the vaccination series by four months of age. The US Centers for Disease Control and Prevention currently recommends that children complete the rotavirus immunization series by six months of age.
Abbott said it has received marketing authorization from the European Commission for a new, lower-strength tablet formulation of HIV protease inhibitor, Kaletra (lopinavir/ritonavir).